Literature DB >> 8830658

Quantification of presenilin-1 mRNA in Alzheimer's disease brains.

J A Johnston1, S Froelich, L Lannfelt, R F Cowburn.   

Abstract

The presenilin-1 (PS-1) gene on chromosome 14 carries mutations which cosegregate with early-onset familial Alzheimer's disease. We quantified PS-1 mRNA in post-mortem mid-temporal and superior frontal cortices from 14 Alzheimer's disease subjects, 9 non-demented controls and 5 subjects with other neurological diseases using solution hybridisation-RNase protection assay. APP and APLP2 mRNAs had previously been quantified in these samples (Johnston et al. (1996) Mol. Brain Res., in press) and subjects were apolipoprotein E (APOE) genotyped. There were no significant differences between PS-1 mRNA levels per pg total RNA in mid-temporal or superior frontal cortices of the Alzheimer's disease subjects, compared to controls. PS-1 mRNA levels corresponded to 10% of total APP and 30% of APLP2 mRNA levels, and were not significantly affected by age, post-mortem delay, tissue pH, or APOE genotype. PS-1 mRNA showed significant positive correlations with APP and APLP2 mRNA levels in mid-temporal cortex and with APP mRNA in superior frontal cortex. This may reflect a co-regulation of the expression of these genes, or the fact that they are expressed in similar neuronal populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830658     DOI: 10.1016/0014-5793(96)00969-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease.

Authors:  Randall L Woltjer; Kevin Duerson; Joseph M Fullmer; Paramita Mookherjee; Allison M Ryan; Thomas J Montine; Jeffrey A Kaye; Joseph F Quinn; Lisa Silbert; Deniz Erten-Lyons; James B Leverenz; Thomas D Bird; David V Pow; Kohichi Tanaka; G Stennis Watson; David G Cook
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

2.  Developmental expression of wild-type and mutant presenilin-1 in hippocampal neurons from transgenic mice: evidence for novel species-specific properties of human presenilin-1.

Authors:  L Lévesque; W Annaert; K Craessaerts; P M Mathews; M Seeger; R A Nixon; F Van Leuven; S Gandy; D Westaway; P St George-Hyslop; B De Strooper; P E Fraser
Journal:  Mol Med       Date:  1999-08       Impact factor: 6.354

3.  Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease.

Authors:  N B Chauhan; J M Lee; G J Siegel
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

4.  Combination therapy prevents amyloid-dependent and -independent structural changes.

Authors:  Gauri Malthankar-Phatak; Shane Poplawski; Nikhil Toraskar; Robert Siman
Journal:  Neurobiol Aging       Date:  2011-01-22       Impact factor: 4.673

5.  Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy.

Authors:  V Askanas; W K Engel; C C Yang; R B Alvarez; V M Lee; T Wisniewski
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

6.  CSF Presenilin-1 complexes are increased in Alzheimer's disease.

Authors:  María-Salud García-Ayllón; María-Letizia Campanari; Gunnar Brinkmalm; Alberto Rábano; Jordi Alom; Carlos A Saura; Niels Andreasen; Kaj Blennow; Javier Sáez-Valero
Journal:  Acta Neuropathol Commun       Date:  2013-08-06       Impact factor: 7.801

7.  Gene Expression of Quaking in Sporadic Alzheimer's Disease Patients is Both Upregulated and Related to Expression Levels of Genes Involved in Amyloid Plaque and Neurofibrillary Tangle Formation.

Authors:  Bryn Farnsworth; Christiane Peuckert; Bettina Zimmermann; Elena Jazin; Petronella Kettunen; Lina Sors Emilsson
Journal:  J Alzheimers Dis       Date:  2016-05-06       Impact factor: 4.472

8.  Physiological genomics analysis for Alzheimer's disease.

Authors:  Viroj Wiwanitkit
Journal:  Ann Indian Acad Neurol       Date:  2013-01       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.